Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) Net Margin (2019 - 2025)

Addex Therapeutics' Net Margin history spans 7 years, with the latest figure at 1923550.4% for Q4 2025.

  • On a quarterly basis, Net Margin fell 128078482.0% to 1923550.4% in Q4 2025 year-over-year; TTM through Dec 2025 was 7366.65%, a 782245.0% decrease, with the full-year FY2025 number at 22448.44%, down 2419448.0% from a year prior.
  • Net Margin came in at 1923550.4% for Q4 2025, down from 642765.58% in the prior quarter.
  • The five-year high for Net Margin was 12465.56% in Q2 2024, with the low at 1923550.4% in Q4 2025.
  • Historically, Net Margin has averaged 151531.03% across 5 years, with a median of 581.67% in 2023.
  • Biggest five-year swings in Net Margin: surged 1280695bps in 2024 and later crashed -128078482bps in 2025.
  • Year by year, Net Margin stood at 5372.48% in 2021, then soared by 105bps to 242.33% in 2022, then tumbled by -2574bps to 5996.05% in 2023, then tumbled by -10620bps to 642765.58% in 2024, then crashed by -199bps to 1923550.4% in 2025.
  • Business Quant data shows Net Margin for ADXN at 1923550.4% in Q4 2025, 642765.58% in Q4 2024, and 4.46% in Q3 2024.